BGI Genomics Co

BGI Genomics Co FCF Growth

The Year-over-Year Free Cash Flow Growth of BGI Genomics Co (300676.SZ) as of Nov 4, 2026 is -31.21 %. In the previous year, Year-over-Year Free Cash Flow Growth was 47.59 % — a change of -165.58% (lower).

FCF Growth

-31.21 %

YoY

-165.58%

Last updated:

Year-over-Year Free Cash Flow Growth of BGI Genomics Co is 2025 -31.21 % . Year-over-Year Free Cash Flow Growth of BGI Genomics Co was 2024 47.59 % . It decreases by -165.58% lower compared to the previous year.

The BGI Genomics Co FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-1,291.75 CNY
Jan 1, 2019
39.38 CNY
Jan 1, 2020
920.90 CNY
Jan 1, 2021
-36.62 CNY
Jan 1, 2022
-154.27 CNY
Jan 1, 2023
27.13 CNY
Jan 1, 2024
47.59 CNY
Jan 1, 2025
-31.21 CNY
The BGI Genomics Co FCF Growth history
YEARFCF GrowthYoY
-31.21 %-165.58%
47.59 %+75.42%
27.13 %-117.59%
-154.27 %+321.32%
-36.62 %-103.98%
920.90 %+2,238.57%
39.38 %-103.05%
-1,291.75 %+331.35%
-299.47 %+177.59%
-107.88 %-185.06%
126.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BGI Genomics Co Stock analysis

What does BGI Genomics Co do? BGI Genomics Co., Ltd. generates revenue through its core services in genomics, including reproductive health basic research and clinical application services, basic science research services such as genome sequencing and bioinformatics analysis, complex disease research and clinical applications, and drug-related research services. The company primarily serves academic institutions, research institutes, independent laboratories, pharmaceutical companies, hospitals, and medical institutions both domestically and internationally. Its domestic market focus allows it to cater to a wide range of clients seeking advanced genomic solutions for research and healthcare applications. The firm's revenue streams are derived from providing specialized genomic services to institutions and companies involved in medical research and healthcare. By offering multithreaded solutions in genome sequencing and bioinformatics, BGI Genomics supports clients in advancing their scientific and clinical objectives. The company's domestic market operations enable it to maintain strong relationships with key stakeholders in China's healthcare and research sectors. BGI Genomics' service portfolio includes reproductive health, complex disease, and drug development research, all of which are critical areas for pharmaceutical and medical institutions. These services are tailored to meet the needs of academic and commercial clients, driving demand for its genomic analysis and research support. The company's focus on domestic operations ensures alignment with local healthcare and research priorities. BGI Genomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BGI Genomics Co stock

Year-over-Year Free Cash Flow Growth of BGI Genomics Co is -31.21 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth BGI Genomics Co since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's BGI Genomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — BGI Genomics Co

All Key Metrics — BGI Genomics Co